The UK and US have concluded a key bilateral deal that will ensure no import taxes on UK medicine products going into the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has pledged to raise expenditure on drugs through the public health system. This pledge secures that import taxes on these vital goods will be held at zero for a duration of the next three years.
This deal is in response to previous warnings to dramatically increase tariffs on patented drug imports, with potential rates mentioned up to one hundred percent.
"This deal between the United Kingdom bolsters the global environment for new treatments and brings long-overdue equity to American-British pharmaceutical trade," a statement noted.
Trade Impact
Pharmaceuticals are one of the the United Kingdom's biggest export categories to the United States, which is by far the primary destination for large companies like GSK and AstraZeneca.
Statistics indicate that in the one-year period prior to last September, the UK exported medicines worth over eleven billion pounds to the US. This figure represented a significant portion of total UK exports in that period.
"This deal safeguards employment, stimulates funding and paves the way for the UK to emerge as a international leader for life sciences," a minister remarked.
Detailed British Pledges
The agreement involves several key pledges from the United Kingdom:
- Revised Affordability Limit: The UK will raise the price threshold at which it deems new medicines to be prohibitively costly by 25%.
- Increased NHS Spending: There is a aim to increase total NHS spending on drugs from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Payback Limit: The sum pharmaceutical firms must pay back to the NHS to stay within budget will be capped at fifteen percent. Last year, rebates topped twenty percent.
Broader Context
The deal takes place against a ongoing row between the sector and the British authorities over drug pricing and approval rates.
This friction were exacerbated by arguments that US patients were charged several times more for the same drugs than people in the other developed nations.
In recent months, several large drug company projects in the UK have been paused or cancelled, while multi-billion-dollar expansions have been announced toward projects in the United States.
A senior figure acknowledged that the NHS must increase expenditure on treatments, noting that its spending on drugs had declined as a percentage of its resources over the past decade.
